"We are pleased to once again enter into a strategic collaboration with Roche, a global leader in oncology, to advance the development of our potential bestinclass DLL ADC candidate. We look forward to combining Innovent's innovative technologies with Roche's scientific insights and global R&D capabilities to jointly advance the accessibility of highquality innovative medicines and benefit more patients around the world as soon as possible."
Boris L. Zaitra, Head of Global Corporate Business Development at Roche , said: "We are pleased to enter into a partnership with Innovent to jointly advance this innovative investigational therapy for the treatment of small cell lung cancer. This collaboration builds on Roche's continued innovation and deep accumulation in the field of ADCs and aims to provide transformative treatments for patients with solid tumors to meet their unmet needs."
Under the agreement, Innovent Biologics granted Roche exclusive rights to global switzerland phone number list development, production and commercialization of IBI. The two parties will jointly be responsible for the early development of the ADC candidate drug, and Roche will be responsible for subsequent clinical development. Innovent Biologics will receive an upfront payment of US$ million, potential development and commercialization milestone payments of up to US$ billion, and tiered sales commissions based on future global annual net sales.